透雲生物(01332.HK)擬收購持續食品生態系統提供解決方案企業
透雲生物(01332.HK)公布,就可能收購目標公司與賣方訂立框架協議。據協議,附屬Clever Spot有意收購目標公司全部已發行股本及未行使購股權,作價待定。
目標公司通過非轉基因微藻技術為生產衣藻推出全新及更適合自己的食品成分。衣藻為食用安全的替代肉類。該公司已開發一種發酵生產過程,藉以擴展生產,並已使用非轉基因技術育種及選擇開發出不同衣藻品種。
目標公司從事為可持續食品生態系統提供解決方案,以提供更富營養、更健康及更美味的食物。並已與一名美利堅合眾國植物性肉類生產商合作,將含有非轉基因微藻的新型藻類肉類創新產品推出市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.